Pharmacopeia

Canonical comparison

Master Compare

Compare candidate-facing canonical Pharmacopeia fields side by side. Isolated AI-draft proposals are never included.

2selected
Comparing 2 of 2 drugs
× ×
Change selection
2 drug columns · use arrows or scrollbar
Field DIGOXIN ANTIBODIES
Antidotes · Antidotes · Level 3
NALOXONE
Antidotes · Antidotes · Level 3
Mechanism of action

Binds excess digoxin or digitoxin molecules circulating in the blood
- Fab fragment-digoxin complex excreted by kidney - Net shifts the equilibrium away from binding of digoxin to receptors

Reversal of MoP receptor effects such as sedation, hypotension, respiratory depression, and the dysphoric effects of partial agonists
Will precipitate acute withdrawal symptoms in opiate addicts

Physiological effects —

- CVS: > 0.3 mg/kg → ↑MAP
- RESP: nil
- CNS: Drowsiness at high dose, Decreased pain tolerance
- OTHER: Sphincter of oddi spasm

Absorption

-

91% absorption but Oral BA 2% due to extensive first-pass metabolism

Protein binding

-

46%

Volume of distribution

0.3 L/kg [DigiFab]
0.4 L/kg [Digibind]

2 L/kg
Highly lipid soluble

Metabolism

Nil

Liver
via glucuronidation to naloxone-3-glucouronide

Excretion

Urine

—
Clearance —

25 ml/min/kg

Half-life

Unbound: 11 hrs
Bound: 15-20 hrs

0.5-1.5 hrs

Adverse Effects Toxicity

Anaphylaxis – rare
Digoxin Withdrawal: AF, heart failure, hypokalemia

Rapid onset of withdrawal symptoms in opioid drug addiction
At High Doses:
- Hypertension
- Tachycardia
- Arrhythmias

Chemical Pharmaceutics

Monoclonal antibody (mAB) FAB (Fragment antigen-binding) fragment from sheep immunized with digoxin derivative

substituted oxymorphone derivative.
pKa = 8.0

Class Group

Antidote

Antidote

Indications Uses

- For treatment of acute and chronic digoxin overdose
- Treatment of toxicities of other cardiac glycosides: oleander, bufotoxin (cane toad), Chinese medicines

- the reversal of respiratory depression due to opioids
- the diagnosis of suspected opioid overdose and has been used in the
treatment of.
- clonidine overdose

Legacy Cicm Level

Level 3

Level 3

Main Action

Binds Digoxin Molecules

competitive antagonist at mu-, delta-,
kappa-, and sigma-opioid receptors

Onset Peak Duration

Onset: 0-60min
Peak: 30-360min

Onset: 1-3 mins
Peak effect: 15 mins
Duration: 30 mins
> Less than the effect site time of most opioids → requirement for repeat dosing or infusion.

Presentation

powder
contains 38-40mg of digoxin-specific Fab fragments (which binds approx. 0.5mg Digoxin)
reconstitute with sterile water

clear solution for injection containing 0.02/0.4 mg/ml of naloxone hydrochloride

Route And Dose

IV

Empiric: 10vials of Fab fragments

Known dose, no level:
Total body load = Dose (in mg) x 0.8 (BA of digoxin)
Number of vials = TBL x 2

Known concentration:
No of vials = [(serum digoxin concentration in ng/mL) x (patient's weight in kg)]/ 100

IV/IM

- Reversal of post-operative respiratory depression and coma: 20-40mcg IV PRN
- For opioid overdose reversal 0.4-2 mg IM/IV → Via infusion a 5mcg/kg/hr
- Reversal of S/Es of opioids: 1-4 mcg/kg
- Increased cardiac contractility in septic shock at doses 1mg/kg IV

Special Points —

effective in alleviating the pruritus, nausea,
and respiratory depression associated with the epidural or spinal administration of opioids.